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Abstract
Aim: The International Continence Society (ICS) has standardized quality
control and interpretation of uroflowmetry and urodynamics. We evaluated
traces from two large studies of male lower urinary tract symptoms
(UPSTREAM and UNBLOCS) against ICS standards of urodynamic equipment
and practice.
Methods: Ten percent of uroflowmetry and urodynamics traces were selected
at random from hospital sites. A data capture template was designed from the
ICS Fundamentals of Urodynamic Practice checklist. Two pretrained blinded
assessors extracted the data, with a third assessor to arbitrate. Departmental
records of calibration checks and equipment maintenance were scrutinized.
Results: Seven out of twenty‐five (28%) departments reported no calibration
checks. Four sites (16%) could not provide annual service records. In 32 out of
296 (10.8%) uroflowmetry traces, findings were affected by artifact. One hun-
dred ten urodynamic study traces were reviewed; in 11 records (10%), key
pressure traces were incompletely displayed. In 30 (27.2%), reference zero was
not set to atmospheric pressure. Resting pressures were outside the expected
range for 36 (32.7%). Pressure drift was seen in 18 traces (16.4%). At pressure‐
flow study commencement, permission to void was omitted in 15 (13.6%).
Cough testing after voiding was done in 71.2%, but the resulting cough spikes
were significantly different in 16.5%. Erroneous diagnosis of bladder outlet
obstruction (BOO) was identified in six cases (5.5%).
Conclusions: Erroneous diagnosis of BOO is a serious error of interpretation,
as it could lead to unnecessary surgery. Other errors of standardization, testing,
and interpretation were identified with lower risk of adverse implications.
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Inconsistent documentation of service records mean equipment accuracy is
uncertain.
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1 | INTRODUCTION
Lower urinary tract symptoms (LUTS) in men are a common
reason for referral to urologists, leading to consideration of
surgery for benign prostatic obstruction (BPO). The diag-
nostic assessments for evaluating male LUTS are clearly set
out in several good quality guidelines,1 based on a history
and examination, symptom score, urinalysis, bladder diary,
and uroflowmetry.2 Uroflowmetry is intended to measure
maximum flow rate (Qmax), voided volume (VV) and post‐
void residual (PVR), with an assessment of flow pattern to
give some initial impression of potential causative processes
explaining LUTS.3 Additional testing in the form of ur-
odynamic studies (UDS) may detect detrusor overactivity
(DO) during bladder filling, and whether bladder outlet ob-
struction (BOO) or detrusor underactivity (DU) is responsible
for the men's voiding symptoms. Both the American
Urological Association4 and the European Association of
Urology2 Guidelines indicate that UDS are an optional part
of assessment, but state that only pressure‐flow studies (PFS)
are able to differentiate DU from BPO as the cause of the
men's symptoms. Both uroflowmetry and UDS facilitate
therapy decisions in men with LUTS, and this is especially
significant when considering surgical intervention. Diag-
nostic assessment is mainly designed to focus therapy on
causative mechanisms and therefore try to minimize the risk
of “unnecessary surgery,” or to predict which men may have
suboptimal outcomes if surgery is performed.
Any staff undertaking diagnostic tests need to have
adequate training and experience in ensuring that testing
is done to appropriate quality standards and under-
standing the implications of results for decision‐making.
The International Continence Society (ICS) working
groups have proposed the current approaches to stan-
dardization, quality control, and interpretation of uro-
flowmetry and UDS.3,5‐8 There are several key aspects
with implications for test results:
1. Adherence to the ICS good urodynamic practices5,6
ensures standardization so that tests reliably derive the
main observations and results can be compared.
2. Monitoring the technical aspects in real time during
the test helps ensure prompt intervention to reduce
the incidence of artifacts.9,10
3. Post‐test processing is needed to ensure that key me-
trics to derive urodynamic observations are not taken
at the time of an artifact and to calculate indices.
4. Sometimes a test is identified as unrepresentative of
day‐to‐day life, notably as a result of patient anxiety or
the artificial nature of the testing situation.
5. A department doing clinical testing regularly needs to
ensure that the equipment measures values reliably,
undertaking departmental calibration checks every
10 tests.11
6. Annual maintenance and checks of system perfor-
mance should also be undertaken.7
These are complex issues requiring experience to achieve
UDS testing in line with the required standards. Nonetheless,
a wide range of staff come into contact with patients during
the male LUTS assessment pathway, including doctors and
nurses at various career stages. Thus, each department needs
to ensure adequate training and scrutiny of performance.
UPSTREAM12 and UNBLOCS13 are two large UK‐
based studies set in 30 different urology departments,
studying the therapeutic pathway for male LUTS. UP-
STREAM is a randomized controlled trial assessing ur-
odynamic testing for the diagnosis and management of
BOO in men. UNBLOCS is a randomized controlled trial
to determine the clinical and cost effectiveness of thu-
lium laser vaporesection of the prostate vs standard
transurethral resection. The aim of this paper is to assess
the quality of a sample of the uroflowmetry and UDS data
from the two studies.
2 | METHODS
Uroflowmetry was undertaken in both UNBLOCS and
UPSTREAM trials, with UDS testing also undertaken
in the UPSTREAM trial. Two sites overlapped between
the two trials. Ten percent of uroflowmetry (30 sites)
and urodynamics traces (26 sites) were selected at
random from sites. A data capture template was de-
signed from the ICS Fundamentals of Urodynamic
Practice checklist7 to examine parameters that could be
identified from source traces and data (Table 1). Two
pretrained blinded assessors (MA, JJ) independently
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extracted the data for each trace. Where there was
disagreement, a third assessor (MJD) arbitrated the
conclusion. Trace scrutiny evaluated the presence of
recognized urodynamic features and artifacts9,10 and
adherence to the ICS good urodynamic practices5,6;
nonadherence was categorized as an error of standar-
dization. Apparent failure to ensure real‐time mon-
itoring and correction of artifacts was categorized as an
error of technique. Post‐test processing was checked to
ensure that urodynamic observations were not taken at
the time of an artifact, and to validate the derived in-
dices (BOO Index [BOOI] and Bladder Contractility
Index [BCI]14). Inaccuracy at this stage was categorized
as an error of interpretation. Where applicable,
patterns of flow rate were categorized as normal,
intermittent, compressive (classically BPO), or con-
strictive (typically urethral stricture) as specified in the
ICS good urodynamic practices documents.5,6 In addi-
tion, an “indeterminate” category was included, where
a flow pattern could not be attributed to an established
category.
In addition, each participating research site in the
UPSTREAM trial was asked to provide routine de-
partmental records of regular calibration checks
to evaluate against ICS standards on urodynamic
equipment.11 These were examined to look for
evidence of the calibration of the flow meters (volume
and flow rate measurement) and the pressure
transducers used to measure vesical (Pves) and ab-
dominal pressure (Pabd). Copies of annual equipment
TABLE 1 Quality and interpretation recommendations (derived from Gammie and Drake3 and Schafer et al6)
Question/subject Solution/guideline
Uroflowmetry3
Is the trace clear of artifacts from the movement of body,
flow meter or urine stream?
Adjust trace markers if possible and instruct patient for improved
next flow
Is Qmax marked at a point away from artifacts? Move Qmax marker to smoothed maximum position
Are the markers for start and end of void away from
artifacts or drops of urine?
Move markers away from artifacts
Does the scale of printing make the flow trace clearly
visible?
Adjust scale of display/print
Has the residual urine volume been measured immediately
after voiding?
Measure volume, including comment on any time delay
Cystometry and pressure‐flow study7
Quality
Zero to atmosphere Ensure taps are closed to patient and open to air when zero is pressed
Check resting pressures are normal Supine: Pabd and Pves, 5 to 20 cmH2O
Seated: Pabd and Pves, 15 to 40 cmH2O
Standing: Pabd and Pves, 30 to 50 cmH2O
For all positions: Pdet, −5 to +5 cmH2O
Continuous monitoring Check regularly that pressure transmission is equal on both lines, for
example, coughs, blowing
Check that live patient signal is present throughout
Check that baseline pressures do not drift
Troubleshoot above during the test, temporarily stopping recording/
filling, if necessary
Stop or reduce fill rate if urgency is excessive or compliance is poor
Change patent position as required (eg, discomfort, stress testing)
Consider repeating test if urodynamic question not answered
Interpretation Place markers on the trace frequently, for example, sensation, patient
position, stress tests, permission to void
Adjust positions of markers after completion of test, if needed
Take care when interpreting, for example, rectal contractions, knocking
of flow meter
Equipment records11
Documented calibration checks Ensure calibration is checked and documented regularly
Equipment maintenance records Ensure equipment maintenance is carried out and recorded
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maintenance records were also requested. The anon-
ymized database of UDS trace reviews and calibra-
tion/maintenance records is given in Supporting
Information Material S1.
3 | RESULTS
3.1 | Equipment calibration and
maintenance
Twenty‐five of twenty‐six UPSTREAM sites (96%) responded
to a review of departmental calibration and annual main-
tenance records. The calibration of flow meter volumes was
undertaken by 12 out of 25 (48%). Calibration of flow meters
and pressure transducers was catalogued in 4 out of 25 (16%)
and 8 out of 25 (32%), respectively. The method of transducer
calibration was with a water column by 4 out of 8 (50%), and
reliance on internal equipment “self‐calibration” in the rest.
Where undertaken, 66% of sites undertook them monthly or
more often. Seven out of twenty‐five (28%) urodynamic de-
partments reported no calibration checks. In terms of ur-
odynamic equipment maintenance, 19 out of 25 (76%)
departments held an on‐site annual service record. A further
two sites (8%) reported an annual service contract with re-
cords held externally by the manufacturer of the urodynamic
equipment. Four sites (16%) were unable to provide con-
firmation of annual servicing, of which two also did no
regular department equipment calibration checks.
3.2 | Uroflowmetry testing
Three hundred thirteen uroflowmetry traces selected at
random were reviewed from 30 sites. Of these, 14 traces
from 10 centers (4.5%) could not be analyzed, as the
patient was unable to do a flow test or did not comply
with test requirements (10 of these had a bladder diary
showing the largest void volume was above 150mL).
Accordingly, 299 traces were used for analysis. These
came from 236 patients, as 48 patients from 15 sites did
two flows, and another 15 from four sites did more than
two flows.
The uroflowmetry traces did not display the volume
or maximum flow rate (Qmax) values in 47 out of 299
(15.7%) from 17 sites. Voided volume was missing in 11
out of 299 (3.7%), Qmax in 12 (4.0%), and PVR in 43
(14.4%). Flow pattern was categorized as normal in 55 out
of 296 (18.6%), indeterminate in 49 (16.6%), intermittent
in 3 (1.0%), compressive in 163 (55.1%), or constrictive in
5 (1.7%), and 21 were considered uninterpretable (7.1%).
In 32 out of 296 traces (10.8%), the Qmax informa-
tion was affected by an artifact. This took the form of
an interruption of flow followed by a spiked increase
of flow rate in 13, a spike without preceding inter-
ruption in 5, and suspected Valsalva or strain in 14. In
only 2 out of 32 was a correction applied after the
study to derive Qmax data from a part of the trace
unaffected by an artifact.
Consistency of information between the source trace and
the test report was checked in 289 traces. Errors in values on
the test report were identified in 90 (31%) traces from 14
sites, with each 3 of the 14 sites responsible for 10 or more
consistency errors. The errors affected documentation of VV
in 26 out of 90 (28.9%), Qmax in 23 (25.6%), and PVR in
41 (45.6%).
3.3 | Urodynamics review
One hundred twenty‐three traces were provided from 26
sites, of which 13 were excluded (1 due to poor quality
FIGURE 1 Examples of some of the quality control issues evaluated during urodynamics. Purple arrow: pressures set to reference zero
while recording from patient. Black arrow: downward pressure drift in abdominal pressure. Blue arrows, open arrow: cough before void
which is only picked up in the abdominal pressure; closed arrow: lack of cough test after conclusion of the void. Yellow arrow: start of void.
Green arrow: drop in abdominal pressure during void. Vesical pressure shows a lack of fine detail and poor cough spikes, without a
flush‐through needed to attempt remedial action
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reproduction, 1 because the test was not done, 7 because
only a typed report was provided, and 4 for unspecified/
unknown reasons), giving an analysis set of 110 traces. In
these, some features of the filling cystometry traces were
not clearly reproduced for 11 traces. Features of the PFS
could not be evaluated in three traces, including two
patients who were unable to void during the test.
Three particular errors of standardization were
identified:
1. Wrong display sequence of traces. In 11 records (10%),
the pressure traces of key data (Pves or Pdet) were in-
complete as high values went off‐scale, as a result of
being placed too high in the display sequence.
2. Failure to set atmospheric pressure as the zero re-
ference (Figure 1). In 30 out of 110 (27.2%) traces from
14 sites, the zero‐reference pressure was not set to
atmospheric pressure; instead, the “zero all” software
command was given when transducers were recording
from the patient.
3. Annotations to indicate aspects of the test were often
not provided. For example, the position in which the
test was run (seated or standing) was not marked in 90
(81.8%), and markers indicating provocation tests were
not present in 98 (89.1%). Normal and abnormal
subjective sensation markers (at least one of the first
sensation of filling, normal desire to void, strong de-
sire to void, or urgency) were generally included; they
were missing in six (from four3 sites, with three from
one site). At the start of the PFS, permission to void
(indicated by markers such as “start void”/“voiding”/
“PFS”) was not marked in 15 out of 110 (13.6%) from
six sites.
Several errors of technique were identified in a high
proportion of cases:
1. Unreliable pressure recording (Figure 1). Resting
pressures, at the start of filling, were outside the ex-
pected range for 36 out of 110 traces (32.7%) from 16
sites (expected ranges used were 30 to 50 cmH2O in
the standing position and 15 to 40 cmH2O if seated;
where position was not stated when the range used
was 15 to 50 cmH2O). The resting detrusor pressure
(Pdet) at the start of filling cystometry was outside the
range −5 to +5 cmH2O in 14 (12.3%) from 7 sites.
Regular transmission checks of pressure (individual
coughs) were lacking in 14 (12.7%) from 7 sites. A drift
in one of the pressure lines was seen in 18 traces
(16.4%) from 11 sites. Only one trace did not appear to
have a “live” signal.
2. Failure to interrupt filling in the event of urgency, DO
or reduced compliance as per ICS recommendations.7
Due to limited annotation or lack of filling rate in-
formation, this feature could not be evaluated in 75
out of 110 (68.1%). In the 35 traces where it could be
evaluated, it was done in 3 out of 35 (8.6%), not done
in 15 (42.9%), and did not apply (no urgency, DO or
impaired compliance present) in 17 (48.8%).
3. A cough test before voiding (ie, between stopping filling
and start of voiding) was not done in 48 (43.6%); a
prevoid cough showing bad subtraction (Figure 1),
which was not dealt with before voiding, was seen in 1
case (bad pressure transmission of Pabd); and the cough
test was apparent and showed good subtraction in 61
(55.5%). Cough testing after voiding was done in 79
(71.2%), but the resulting cough spikes were sig-
nificantly different (≥30% height discrepancy between
the respective spikes in the abdominal and vesical
pressure traces) in 13 out of 79 (16.5%), resulting in
large subtraction artifacts on Pdet. Both the pre‐ and
post‐voiding cough tests were missing in 24; for another
16 studies, it was missing in 1 and inaccurate in the
other (without action taken to correct the poor quality).
3.4 | Interpretation of urodynamics
traces
PFS traces with derived voiding parameters (BOOI and
BCI) were available for 107 patients (97.3%): central re-
view diagnosis was assumed to be the correct calculation
from the raw data. For diagnosis of BOO, there was an
agreement between sites and central review for 71% of
traces where BOO was present (BOOI > 40), 79% where it
was equivocal (BOOI, 20‐40), and 42% of men who were
unobstructed (BOOI < 20) (Table 2). Particularly notable
was the group of 19 patients for whom central review was
unable to derive a BOOI value, although sites gave a di-
agnosis for 15 of them, among whom 10 were given a
diagnosis of BOO. The level of agreement was the lowest
for the diagnosis of DU; being only 52% where DU was
present (BCI < 100) and 31% where it was absent
(BCI > 100). For 21 patients, central review was unable to
derive a BCI value, for whom sites gave a diagnosis for 4
(2 of these being given a diagnosis of BOO). Data about
the urodynamic observation of DO was available for 99
traces (90.0%). Fewer traces were evaluable for DO, as
some sites did not provide traces that included filling
cystometry. There was agreement between central review
and site categorization in 57% of available traces where
DO was present, and 51% where it was absent (Table 2).
The reviewers also identified additional factors
needing caution when deriving BOOI and BCI, namely,
straining at the time of Qmax in 15 out of 99 (15.2%),
voiding data derived from a DO incontinence episode in 4
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out of 99 (4.0%), and a major drop in Pabd sufficient to
alter BOO diagnosis in one case. Annotation of key vo-
lumes (trace or attached data) was lacking for PVR in 37
out of 110 (33.6%), cystometric capacity in 35 (31.8%), and
VV in 15 (13.6%). Twenty‐four of those traces missing key
volume data (21.8% of the 110‐sample population) were
missing two or more of the volumes.
4 | DISCUSSION
Questions exist regarding the influence of technique on the
utility and perceived value of urodynamics.15 The findings
from the analysis of UDS and uroflowmetry data indicate
that a detailed quality control process is essential for research
involving urodynamics, and supports the importance of de-
veloping accreditation/reaccreditation schemes for all health
care professionals running these types of test. The UK
Continence Society recently reviewed its minimum stan-
dards for urodynamics, mindful of the fact that there is
concern over the quality of urodynamic testing in practice,16
and the report has been endorsed by the ICS. Experience of
central reading of urodynamic traces from multicenter stu-
dies on therapies have reinforced this concern and made it
clear that this is an international issue (Abrams and
Gammie, personal communication, December, 2019).
Therefore, it is most important that all research studies with
reliance on UDS assess the quality of their tests. In the
current data review, we identified an erroneous diagnosis of
BOO in 6 cases (5.5%), indicated by a site diagnosing BOO
when the central review categorized the BOOI is less than 20.
This has to be regarded as a serious error of interpretation, as
it could lead to major consequences, such as unnecessary
surgery. There is a significant chance that this figure could
underestimate the true extent of the problem in wider
practice. This is because we applied a high level of con-
fidence before labeling a conclusion as erroneous. Further-
more, these were well‐resourced high‐quality research
studies, which implies a clearer focus on diagnostics than
what may be applied in other contexts.
Copies of on‐site records of calibration and equip-
ment maintenance were also checked for compliance
with the ICS recommendation that calibration checks
are done every 10 tests.11 If the calibration of any piece
of equipment is inaccurate, then it should be recali-
brated by a qualified individual before the next test to
avoid recording inaccurate data for a patient. In addi-
tion, annual maintenance checks will cover the system
in more detail, for example, whether the infusion pumps
are delivering liquid at the specified rate. Twenty‐eight
percent of urodynamic sites did not record any depart-
mental calibration checks, and 16% were unable to
provide confirmation of annual service. This means that
the equipment accuracy may not necessarily have been
reliable. While the extent to which this genuinely im-
pacted individual cases cannot be measured, it is an
avoidable risk that can be minimized by adhering to
suitable standards.
The need for caution when interpreting studies also arose
because sites sometimes failed to identify a potential re-
cording problem at the crucial moment of Qmax. For uro-
flowmetry across two major trials in the United Kingdom,
TABLE 2 Prevalence rates of the urodynamic observation of DO and pressure‐flow diagnosis of BOO and DU, comparing central review
findings with categorizations by sites
Categorization by central review Categorization by sites
Observation/diagnosis Prevalence Correct (n) Correct (%) Incorrect (n) Uncategorized (n) Non‐correct (%)
DO present 46/99 (46.4%) 26/46 57% 1/46 19/46 43%
DO absent 53/99 (53.6%) 27/53 51% 2/53 24/53 49%
BOO present (BOOI > 40) 55/107 (51.4%) 39/55 71% 1/55 15/55 29%
BOO equivocal (BOOI 20–40) 14/107 (13.1%) 11/14 79% 3/14a 0/14 21%
Unobstructed (BOOI < 40) 19/107 (15.9%) 8/19 42% 6/19 5/19 58%
Unable to derive BOOI 19/107 (15.9%) N/A N/A 15/19b 4/19 1%
DU present (BCI < 100) 27/107 (25.2%) 14/27 52% 2/27 11/27 48%
DU absent (BCI > 100) 59/107 (55.1%) 18/59 31% 1/59 40/59 69%
Unable to derive BCI 21/107 (19.6%) N/A N/A 4/19c 15/19 1%
Note: “Uncategorized” indicates that the site provided the trace but did not make a comment on diagnosis.
Abbreviations: BCI, Bladder Contractility Index; BOOI, BOO Index; DO, detrusor overactivity; DU, detrusor underactivity; N/A, not applicable.
aCategorized as obstructed in two, unobstructed in one.
bCategorized as obstructed in 10.
cCategorized as DU in two.
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the Qmax information was affected by an artifact in 11%, and
in the majority no correction was applied after the study to
derive flow rate data from a part of the trace unaffected by
the artifact (“corrected Qmax”). For PFS, cough testing after
voiding was omitted in 29% and was significantly inaccurate
(≥30% height discrepancy between the pressure spikes) in
17%, making the reliability of the P Qdet max value uncertain.
Sites sometimes did not run tests in accordance with
the ICS standardizations. For UDS tests, this included
not setting the reference zero pressure to atmospheric
pressure (27%) and limited annotation of traces to help
interpretation (eg, permission to void not marked in
14%). This generally does not have direct implication for
an individual patient test, though sometimes it may
obscure a pressure recording error not picked up by
discrepancy in the cough pressure spikes. However, it
makes comparisons between centers very difficult,
which is unhelpful for standard audit and exploratory
research. In the United Kingdom, the Improving Quality
in Physiological Services (IQIPS; https://www.ukas.
com/services/accreditation‐services/physiological‐
services‐accreditation‐iqips/) scheme allows sites to be-
come accredited against good practice standards that
encompass patient experience, facilities, safety, and
technical quality. The results we present here show that
there is a need for such accreditation to enable depart-
ments to demonstrate and maintain good practice for
patient benefit.
The strengths of the current study were the use of quality
control protocols derived from the ICS Fundamentals of
Urodynamic Practice document,7 random trace‐selection,
and using specifically trained central readers blinded to the
sites under review with expert adjudication for resolution of
discrepancy. The main limitation was the necessity to sample
10% of traces, as this may give an unrepresentative picture of
individual site performance, though this does not affect the
overall evaluation.
5 | CONCLUSIONS
This quality control study has shown that there are sig-
nificant issues with respect to equipment maintenance and
calibration, testing procedures, and the interpretation of re-
sults for both uroflowmetry and urodynamics in a large
number of urodynamic units. This has led to a small pro-
portion of men being wrongly characterized as having BOO,
and hence at risk of being counseled inappropriately to
surgery.
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